Recombinant Human CD80 Protein

功能和特点
  • 表达系统: HEK293
  • Accession #: P33681
  • 蛋白标签: His
  • 生物活性: Measured by its binding activity of recombinant human CD80 and recombinant human CD86. The EC50 for this effect is less than 0.412μg/mL.
  • 内毒素水平: <1.0 EU/μg
有货

库存信息

关闭

库存信息

关闭

库存信息

关闭
货号 (SKU) 包装规格 是否现货 价格 数量
rp144122-25μg
25μg 现货 Stock Image
rp144122-100μg
100μg 现货 Stock Image
rp144122-1mg
1mg 期货 Stock Image

基本描述

产品名称 Recombinant Human CD80 Protein
别名 重组人 CD80 蛋白
英文别名 Activation B7-1 antigen | B7 | BB1 | CTLA-4 counter-receptor B7.1
规格或纯度 ActiBioPure™, Bioactive, Animal Free, Carrier Free, Azide Free, ≥95%(SDS-PAGE)
产品介绍


Purity

>95% SDS-PAGE.


Molecular weight informat

The protein migrates as 65-90 kDa under reducing condition due to glycosylation.


Function

Involved in the costimulatory signal essential for T-lymphocyte activation. T-cell proliferation and cytokine production is induced by the binding of CD28 or CTLA-4 to this receptor.

生物活性 Measured by its binding activity of recombinant human CD80 and recombinant human CD86. The EC50 for this effect is less than 0.412μg/mL.
内毒素水平 <1.0 EU/μg
表达系统 HEK293
种属 Human
氨基酸 35-242 aa
序列 VIHVTKEVKEVATLSCGHNVSVEELAQTRIYWQKEKKMVLTMMSGDMNIW PEYKNRTIFDITNNLSIVILALRPSDEGTYECVVLKYEKDAFKREHLAEV TLSVKADFPTPSISDFEIPTSNIRRIICSTSGGFPEPHLSWLENGEEL NAINTTVSQDPETELYAVSSKLDFNMTTNHSFMCLIKYGHLRVNQTFN WNTTKQEHFPDN
纯度 >95% (SDS-PAGE)
蛋白标签 His
蛋白长度 Protein fragment
无载体 Yes
无动物源 Yes
Accession # P33681
来源 重组表达
预测分子量 25.5 kDa

AI解读

图片

Recombinant Human CD80 Protein (rp144122) - Protein Bioactivity
Measured by its binding activity of recombinant human CD80 and recombinant human CD86. The EC₅₀ for this effect is less than 0.412 μg/mL.

Recombinant Human CD80 Protein (rp144122) - SDS-PAGE
2.5 μg/lane of Recombinant Human CD80 was resolved with SDS-PAGE under reducing (R) and non-reducing (N) conditions and visualized by Coomassie® Blue staining, showing a single band at 50.2 kDa.

产品规格参数

应用 Cell culture; Activity Assays
物理形态 冻干(Lyophilized)
储存缓冲液 PBS, pH7.4, containing 5% trehalose.
复溶 Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not Vortex.
储存温度 -20°C储存
运输条件 超低温冰袋运输
稳定性与储存 避免反复冻融循环。在 2-8 ℃ 下保存一个月。分装后在 -80 ℃ 下保存 12 个月。
分子类型 蛋白质

质检证书(CoA,COO,BSE/TSE 和分析图谱)

C of A & Other Certificates(BSE/TSE, COO):
输入批号以搜索分析图谱:

通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!

找到2个结果

批号(Lot Number) 证书类型 日期 货号
ZJ23F0700615 分析证书 23-07-20 rp144122
ZJ23F0700614 分析证书 23-07-20 rp144122

参考文献

1. Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P et al..  (2004)  The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)..  Genome Res,  14  (10B): (2121-7).  [PMID:15489334] [10.1021/op500134e]
2. Vicente Rabaneda EF, Herrero-Beaumont G, Castañeda S.  (2013)  Update on the use of abatacept for the treatment of rheumatoid arthritis..  Expert Rev Clin Immunol,  (7): (599-621).  [PMID:23899231] [10.1021/op500134e]
3. Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA.  (1991)  CTLA-4 is a second receptor for the B cell activation antigen B7..  J Exp Med,  174  (3): (561-9).  [PMID:1714933] [10.1021/op500134e]
4. Selvakumar, A A and 5 more authors..  (1992)  Genomic organization and chromosomal location of the human gene encoding the B-lymphocyte activation antigen B7..  Immunogenetics,  [PMID:1377173]
5. Freeman, G J GJ and 8 more authors..  (1991)  Structure, expression, and T cell costimulatory activity of the murine homologue of the human B lymphocyte activation antigen B7..  The Journal of experimental medicine,  (1): [PMID:1714935]
6. Freeman, G J GJ and 5 more authors..  (1989)  B7, a new member of the Ig superfamily with unique expression on activated and neoplastic B cells..  Journal of immunology (Baltimore, Md. : 1950),  (15): [PMID:2794510]
7. Lanier, L L LL and 7 more authors..  (1995)  CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL..  Journal of immunology (Baltimore, Md. : 1950),  (1): [PMID:7527824]
8. Vandenborre, K K and 5 more authors..  (1999)  Interaction of CTLA-4 (CD152) with CD80 or CD86 inhibits human T-cell activation..  Immunology,  [PMID:10583602]
9. Ikemizu, S S and 7 more authors..  (2000)  Structure and dimerization of a soluble form of B7-1..  Immunity,  [PMID:10661405]
10. Stamper, C C CC and 9 more authors..  (2001)  Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses..  Nature,  (29): [PMID:11279502]
11. Chen, X X, Ji, Z L ZL and Chen, Y Z YZ..  (2002)  TTD: Therapeutic Target Database..  Nucleic acids research,  (1): [PMID:11752352]
12. Gottlieb, Alice B AB and 8 more authors..  (2004)  Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasis..  Clinical immunology (Orlando, Fla.),  [PMID:15093549]
13. Czuczman, Myron S MS and 13 more authors..  (2005)  Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma..  Journal of clinical oncology : official journal of the American Society of Clinical Oncology,  (1): [PMID:15994148]
14. and Kremer, Joel M JM..  (2005)  Selective costimulation modulators: a novel approach for the treatment of rheumatoid arthritis..  Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases,  [PMID:16357751]
15. Hervey, Pauline S PS and Keam, Susan J SJ..  (2006)  Abatacept..  BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy,  [PMID:16573350]
16. Muzny, Donna M DM and 113 more authors..  (2006)  The DNA sequence, annotation and analysis of human chromosome 3..  Nature,  (27): [PMID:16641997]
17. Weyand, Cornelia M CM and Goronzy, Jörg J JJ..  (2006)  T-cell-targeted therapies in rheumatoid arthritis..  Nature clinical practice. Rheumatology,  [PMID:16932686]
18. and Scheinfeld, Noah N..  (2006)  Abatacept: A review of a new biologic agent for refractory rheumatoid arthritis for dermatologists..  The Journal of dermatological treatment,  [PMID:16971318]
19. Tedesco Silva, Helio H, Pinheiro Machado, Paula P, Rosso Felipe, Claudia C and Medina Pestana, Jose Osmar JO..  (2006)  Immunotherapy for De Novo renal transplantation: what's in the pipeline?.  Drugs,  [PMID:16978033]
20. Vincenti, Flavio F and Luggen, Michael M..  (2007)  T cell costimulation: a rational target in the therapeutic armamentarium for autoimmune diseases and transplantation..  Annual review of medicine,  [PMID:17020493]
21. Nogid, Anna A and Pham, David Q DQ..  (2006)  Role of abatacept in the management of rheumatoid arthritis..  Clinical therapeutics,  [PMID:17212998]
22. Leonard, J P JP and 14 more authors..  (2007)  A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma..  Annals of oncology : official journal of the European Society for Medical Oncology,  [PMID:17470451]
23. Kakoulidou, M M, Giscombe, R R, Zhao, X X, Lefvert, A K AK and Wang, X X..  (2007)  Human Soluble CD80 is generated by alternative splicing, and recombinant soluble CD80 binds to CD28 and CD152 influencing T-cell activation..  Scandinavian journal of immunology,  [PMID:17953528]
24. Reynolds, Jennifer J, Shojania, Kam K and Marra, Carlo A CA..  (2007)  Abatacept: a novel treatment for moderate-to-severe rheumatoid arthritis..  Pharmacotherapy,  [PMID:18041889]
25. Maxwell, Lara J LJ and Singh, Jasvinder A JA..  (2010)  Abatacept for rheumatoid arthritis: a Cochrane systematic review..  The Journal of rheumatology,  [PMID:20080922]
26. Zhou, Houjiang H and 6 more authors..  (2013)  Toward a comprehensive characterization of a human cancer cell phosphoproteome..  Journal of proteome research,  (4): [PMID:23186163]
27. Kleinpeter, Patricia and 20 more authors..  (2019)  By Binding CD80 and CD86, the Vaccinia Virus M2 Protein Blocks Their Interactions with both CD28 and CTLA4 and Potentiates CD80 Binding to PD-L1..  Journal of virology,  (1): [PMID:30918073]

溶液计算器

相关技术文章

FAQ
阿拉丁®靶点蛋白